Document:

exv10w72

Exhibit 10.72

Confidential Treatment Requested Under

17 C.F.R. §§ 200.80(b)(4) and 240.24b-2

	 	 	 
	

	 	MassBiologics

University of Massachusetts Medical School

460 Walk Hill Street, Boston, MA 02126
	 

	 	Telephone: 617-474-3000 Facsimile: 617-474-3240

March 27, 2009

Via Email And FedEx

John N. Kapoor, Ph.D., Chairman

Akorn, Inc.

1925 West Field Court, Suite 300

Lake Forest, IL 60045

jkapoor@ejfinancial.com

     Re: Distribution Agreement – Revised Proposal

Dear John:

     I write with respect to resolving various issues arising under the Exclusive Distribution
Agreement, dated as of March 22, 2007, between Akorn, Inc. (“Akorn”) and the Massachusetts Biologic
Laboratories of the University of Massachusetts (“MBL”) (as amended, our “Distribution Agreement”).
MBL makes Akorn the following offer to resolve the parties’ outstanding issues, and to amend the
Distribution Agreement accordingly (the “Offer”):

     1. Amount Owed.  Giving effect to Akorn’s payment of $1,000,000 on March 13, 2009 (the “$1
Million Payment"), Akorn currently owes MBL $5,750,000 million for Td vaccine shipments delivered
and accepted (the “Amount Owed”). Payment of the Amount Owed is past due. 

     2. Failure to Pick-Up. Akorn acknowledges its failure to take delivery of the shipment of
[***...***] doses of Td vaccine scheduled for Akorn’s pick-up on March 11, 2009, as required under
the Distribution Agreement.

     3. Total Amount Owed. In exchange for the Distribution Agreement amendments set out in
Section 6 (Distribution Provisions), Akorn hereby agrees to pay to MBL the additional amount of
$4,750,000 (such amount together with the Amount Owed, the “Total Amount”).  The Total Amount,
therefore, equals $10,500,000.00.

     4. Pay-Off. Akorn shall pay the remaining Total Amount by wire transfer in accordance with
the payment schedule attached as Exhibit A (“Payment Schedule”). Wire transfer instructions are as
follows: 

BANK OF AMERICA, N.A.

 

			
	*	 	CONFIDENTIAL TREATMENT REQUESTED — This language has been omitted and filed separately with the Securities and Exchange Commission.

 

 

Confidential Treatment Requested Under

17 C.F.R. §§ 200.80(b)(4) and 240.24b-2

ABA Routing [***...***]

Account [***...***]

Checking Account

Bank Phone # (800) 432-1000

     5. Standby Irrevocable Letter of Credit. As security for the timely payment by Akorn of the
Total Amount in accordance with the Payment Schedule, and to reimburse MBL in the event any such
payment (or any portion thereof) and/or the $1 Million Payment (or any portion thereof) is avoided,
set aside, or otherwise required to be repaid by MBL (whether pursuant to or in connection with a
bankruptcy or similar proceeding involving Akorn or otherwise), Akorn or its designee shall provide
to MBL on or before April 13, 2009 (the “LOC Delivery Date”) an irrevocable transferable standby
letter of credit that meets the following three criteria: the letter of credit shall be (i) in form
and substance reasonably satisfactory to MBL (provided that MBL shall not make unreasonable
modifications to the bank’s form letter of credit); (ii) in the amount of $10,500,000.00, and (iii)
confirmed by a United States bank acceptable to MBL (the “Letter of Credit”). Provided (x) on or
before April 6, 2009, Akorn delivers to the issuing bank all documents and materials (other than
funding), needed by the bank to issue a Letter of Credit meeting the requirements of the previous
sentence, (y) Akorn does not request changes to this Letter of Credit after April 6, 2009 (unless
the request is objectively based on clear and convincing justification), and (z) the Letter of
Credit is funded by Akorn as of April 13, 2009, then the LOC Delivery Date shall be extended on a
day for day basis for each day of negotiations between MBL and the issuing bank over the form and
substance of the Letter of Credit which continue subsequent to April 13, 2009. MBL will be able to
draw on such Letter of Credit but, in each case, only in the amount not so paid or so avoided, set
aside, or repaid, at such time (a) that any required payment in respect of the Total Amount is not
timely paid according to the Payment Schedule, or (b) that any such payment (or any portion
thereof) is avoided, is set aside, recovered or is otherwise required to be repaid by MBL, or (c)
that the $1 Million Payment (or any portion thereof) is avoided, set aside, recovered or is
otherwise required to be repaid by MBL. Provided that no bankruptcy, receivership or other similar
proceeding is filed by or against Akorn within the 95 day period immediately subsequent to each
payment of the Total Amount in accordance with the Payment Schedule, then the amount of the Letter
of Credit shall be reduced by the amount of such payment, and such reduction shall take place 95
days after each associated payment. The Letter of Credit shall not expire until 95 days after the
sooner to occur of payment in full in immediately available funds of the Total Amount or June 30,
2010, provided, however in the event that prior to the expiration of such 95 day period, a
bankruptcy, receivership or other similar proceeding is filed by or against Akorn, the Letter of
Credit shall not expire until all applicable time limitation periods (including under Section 546
of the Bankruptcy Code) relating to the avoidance, setting aside, recovery or repayment of any
payments made by Akorn to MBL in respect of the Total Amount or the $1 Million Payment shall have
expired and no action, litigation or other proceeding in respect thereof shall have been commenced
against MBL or, if any such action, litigation or other proceeding shall have been so commenced,
the same shall have been resolved by a final order of a court of competent jurisdiction and 5 days
from the entry of such order shall have passed.

     6. Distribution Provisions

 

			
	*	 	CONFIDENTIAL TREATMENT REQUESTED — This language has been omitted and filed separately with the Securities and Exchange Commission.

 

 

Confidential Treatment Requested Under

17 C.F.R. §§ 200.80(b)(4) and 240.24b-2

          6.1 Provisions Taking Immediate Effect. The following amendments to the Distribution
Agreement shall become effective as of Akorn’s acceptance of this Offer:

               6.1.1 Non-Exclusive Distribution. Akorn will no longer act as MBL’s exclusive distributor
under the Distribution Agreement and the Distribution Agreement will be amended to become
non-exclusive. Specifically, Akorn will be one of MBL’s, but not the sole, FDA authorized
distributors.

               6.1.2 Pricing; Reduced Pricing. Pricing to Akorn for Td Vaccine shall be as set out in the
Distribution Agreement; provided, however, that if MBL offers more favorable per dose pricing to
MBL’s other distributors (“Reduced Per Dose Pricing”), then (i) MBL shall notify Akorn, and (ii)
during the period of such Reduced Per Dose Pricing, MBL shall offer the same Reduced Per Dose
Pricing to Akorn on orders that Akorn places and takes delivery on, during such period. These
Reduced Per Dose Pricing provisions shall not apply to any Td Vaccine sold by MBL under contracts
arising from CDC Solicitation Number 2009-N-11074 Vaccine for Children, and MBL’s pricing under
such contracts shall not be effected by MBL’s relationship with Akorn. MBL and others will be
entitled to sell to others MBL’s Td Vaccines product labeled with Akorn’s NDC currently in MBL’s
possession.

               6.1.3 Suspension of Minimum Purchase Obligations. Akorn’s obligation to make any further
minimum purchases of Td vaccine products and to otherwise comply with the delivery schedule set out
in the Distribution Agreement is hereby suspended through the LOC Delivery Date.

          6.2 Provisions Taking Effect upon Delivery of LOC. On the strict condition that, in
compliance with the terms of this Offer, MBL receives the Letter of Credit on or before the LOC
Delivery Date (the “Required Condition”), the following amendments to the Distribution Agreement
will go into effect as of the LOC Delivery Date:

               6.2.1 Removal of Minimum Purchase Obligation. Upon fulfillment of the Required Condition (and
under no other circumstances), the Distribution Agreement shall be amended such that Akorn will not
be obligated to make any minimum purchases of Td vaccine products and will purchase on an as needed
basis with the quantity to be mutually agreed.

               6.2.2 Resale on Termination; Termination without Cause. Upon fulfillment of the Required
Condition (and under no other circumstances), the Distribution Agreement will also be amended to
include a revised termination provision eliminating the prohibition on the resale of product in the
event of a termination for cause and giving either party the right to terminate the agreement for
any reason without penalty on 90 days written notice; provided, however, that such right to
terminate without cause shall not affect Akorn’s obligations under sections 1, 3, and 4, above, or
MBL’s rights hereunder (including under Section 5, above) or under the Letter of Credit or the
Documents. Until termination thereof, Akorn would remain subject to all other provisions of the
Distribution Agreement (except as such provisions are expressly amended in accordance with this
proposal).

 

			
	*	 	CONFIDENTIAL TREATMENT REQUESTED — This language has been omitted and filed separately with the Securities and Exchange Commission.

 

 

Confidential Treatment Requested Under

17 C.F.R. §§ 200.80(b)(4) and 240.24b-2

     7. Payment Terms. For all future orders under the Distribution Agreement, payment terms will
be that Akorn shall pay for the order in full in cash upon placing the order with MBL.

     8. Amended Cure Period. Akorn agrees that the cure period set out in Section 11(a) of the
Distribution Agreement is hereby amended such that, notwithstanding anything to the contrary
contained in the Distribution Agreement, (a) Akorn’s ability and right to cure defaults or other
breaches of the Distribution Agreement in existence as of the date of this Offer shall expire as of
the LOC Delivery Date, and (b) the Distribution Agreement automatically shall terminate if, as of
the expiration of the LOC Delivery Date, Akorn has failed to fulfill the Required Condition.

     9. Information.  For the remaining duration of the Distribution Agreement, Akorn will deliver
to MBL by the fifth business day of each month (i) a monthly cash forecast for the MBL Td Vaccine
product to be sold pursuant to the Distribution Agreement (as amended by this letter agreement);
and (ii) monthly inventory and sales information for the MBL Td Vaccine product. Additionally
Akorn will deliver to MBL quarterly financial results as and when filed with the SEC.

     10. Documents. Documents necessary to implement, or being delivered in connection with, this
Offer (including a forbearance agreement) (collectively, the “Documents”), shall conform in all
respects to the terms of this Offer, and shall otherwise be in form and substance mutually
reasonably acceptable to Akorn and MBL, provided. Akorn shall deliver draft Documents to MBL as
soon as practicable and the parties will work together in good faith to execute the Documents on or
before the LOC Delivery Date.

     11. Forbearance. So long as Akorn complies with the terms hereof, the amended Distribution
Agreement, and the Documents, MBL will forebear from declaring a breach or otherwise acting to
terminate the Distribution Agreement, as amended hereby and in connection herewith.

     12. Binding Effect. All terms material to the parties’ resolution of the current issues under
the Distribution Agreement are contained in this Offer and, once accepted by Akorn, these terms
shall be legally binding and fully enforceable.

     If this Offer meets with your approval, please accept this Offer by signing below, and then
return to me one fully executed copy of this Offer no later than 10:00 p.m., EDT March 27, 2009,
after which date this Offer will expire.

	 	 	 	 	 
	 	 	Very truly yours,

	 	 	Massachusetts Biologic Laboratories of the University
	 	 	of Massachusetts Medical School
	 
	 	 	 	 
	 

	 	By:
	 	/s/ Donna M. Ambrosino, M.D.
	 

	 	Name:
	 	Donna M. Ambrosino, M.D.
	 

	 	Title:
	 	Director

 

			
	*	 	CONFIDENTIAL TREATMENT REQUESTED — This language has been omitted and filed separately with the Securities and Exchange Commission.

 

 

Confidential Treatment Requested Under

17 C.F.R. §§ 200.80(b)(4) and 240.24b-2

Agreed and Accepted by

The undersigned hereby agrees to and accepts the Offer, as of March 27, 2009.

	 	 	 	 	 
	 	 	Akorn Inc.
	 
	 	 	 	 
	 

	 	By:
	 	/s/ John N. Kapoor, P.h.D.
	 

	 	Name
	 	: John N. Kapoor, P.h.D.
	 

	 	Title:
	 	Chairman, Duly Authorized

 

			
	*	 	CONFIDENTIAL TREATMENT REQUESTED — This language has been omitted and filed separately with the Securities and Exchange Commission.

 

 

Confidential Treatment Requested Under

17 C.F.R. §§ 200.80(b)(4) and 240.24b-2

EXHIBIT A

Payment Schedule

	 	 	 	 	 	 	 	 	 
	Payment Date	 	Amount of Payment	 	Remaining Balance
	Balance Due, March 18, 2009
	 	 	 	 	 	$	10,500,000.00	 
	April 13, 2009
	 	$	1,000,000.00	 	 	$	9,500,000.00	 
	May 13, 2009
	 	$	1,500,000.00	 	 	$	8,000,000.00	 
	June 13, 2009
	 	$	2,000,000.00	 	 	$	6,000,000.00	 
	July 13, 2009
	 	$	1,500,000.00	 	 	$	4,500,000.00	 
	August 13, 2009
	 	$	1,500,000.00	 	 	$	3,000,000.00	 
	September 13, 2009
	 	$	1,500,000.00	 	 	$	1,500,000.00	 
	June 30, 2010
	 	$	1,500,000.00	 	 	$	0.00	 

 

			
	*	 	CONFIDENTIAL TREATMENT REQUESTED — This language has been omitted and filed separately with the Securities and Exchange Commission.EX-10.1

Exhibit 10.1

THIRD AMENDMENT TO CREDIT AGREEMENT

     THIS THIRD AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of March 24,
2009, is by and among BELDEN INC. (formerly known as Belden CDT Inc.), a Delaware corporation (the
“Borrower”), those Material Domestic Subsidiaries of the Borrower party hereto (each a
“Guarantor” and collectively, the “Guarantors”), and WACHOVIA BANK, NATIONAL
ASSOCIATION, as administrative agent on behalf of the Lenders (as hereinafter defined) under the
Credit Agreement (as hereinafter defined) (in such capacity, the “Administrative Agent”).
Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed
thereto in the Credit Agreement.

W I T N E S S E T H

     WHEREAS, the Borrower, the Guarantors, certain banks and financial institutions from time to
time party thereto (the “Lenders”) and the Administrative Agent are parties to that certain
Credit Agreement dated as of January 24, 2006 (as amended, modified, extended, restated, replaced,
or supplemented from time to time, the “Credit Agreement”);

     WHEREAS, the Credit Parties have requested the Lenders agree to amend certain provisions of
the Credit Agreement; and

     WHEREAS, the Required Lenders are willing to make such amendments to the Credit Agreement,
subject to the terms and conditions set forth herein.

     NOW, THEREFORE, in consideration of the agreements hereinafter set forth, and for other good
and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties
hereto agree as follows:

ARTICLE I

AMENDMENTS TO CREDIT AGREEMENT

     1.1 Amendments to Section 1.1.

     (a) The following definitions are hereby added to Section 1.1 of the Credit Agreement
in appropriate alphabetical order:

     “Deferred Margin” shall mean, as of any date of determination, an
amount equal to the sum of revenues deferred as of such date minus the cost
of goods sold deferred as of such date, in each case as a result of the application
of Statement of Position 97-2, “Software Revenue Recognition” and determined in
accordance with GAAP.

     “Third Amendment Effective Date” shall mean March ___, 2009.

 

     (b) The pricing grid in the definition of “Applicable Percentage” is hereby amended and
restated in its entirety to read as follows:

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Total	 	LIBOR Margin	 	 	 	 
	Level	 	Leverage Ratio	 	& L/C Fee	 	Base Rate Margin	 	Commitment Fee
	I

	 	3 3.00 to 1.0
	 	 	2.75	%	 	 	1.75	%	 	 	0.50	%
	II

	 	3 2.00 to 1.0
but < 3.00 to
1.0
	 	 	2.50	%	 	 	1.50	%	 	 	0.375	%
	III

	 	3 1.00 to 1.0
but < 2.00 to
1.0
	 	 	2.25	%	 	 	1.25	%	 	 	0.375	%
	IV

	 	< 1.00 to 1.0
	 	 	2.00	%	 	 	1.00	%	 	 	0.25	%

     (c) The definition of “Applicable Percentage” is hereby amended by adding the following
sentence to the end thereof:

     Notwithstanding the foregoing, the Applicable Percentage shall be as set forth
above opposite Level II beginning on the Third Amendment Effective Date through
(but not including) the first Interest Determination Date after the Third Amendment
Effective Date.

     (d) The definition of “Consolidated EBITDA” is hereby amended and restated in its
entirety to read as follows:

     “Consolidated EBITDA” shall mean, as of any date of determination for
the four fiscal quarter period ending on such date, the sum of (a) Consolidated Net
Income for such period, plus (b) the sum of the following to the extent
deducted in calculating Consolidated Net Income: (i) Consolidated Cash Interest
Expense for such period, (ii) tax expense (including, without limitation, any
federal, state, local and foreign income, value added, franchise, withholding and
similar taxes) of the Credit Parties and their Subsidiaries for such period, (iii)
depreciation, amortization, share-based compensation expense and other non-cash
charges (excluding non-cash charges that are expected to become cash charges in a
future period or that are reserves for future cash charges) for such period, and
(iv) one-time charges incurred in connection with restructuring activities prior to
the Third Amendment Effective Date, as set forth on Schedule 1.1(d), and
other one-time charges incurred in connection with restructuring activities after
the Third Amendment Effective Date in an amount not to exceed the amounts set forth
on Schedule 1.1(e) plus (c) the increase, if any, in the amount of
Deferred Margin from the beginning of such period to the end of such period,
minus (d) the decrease, if any, in the amount of Deferred Margin from the
beginning of such period to the end of such period.

2

 

     1.2 Replacement Schedule 1.1(d) and 1.1(e). Schedules 1.1(d) and 1.1(e) to the Credit
Agreement are hereby replaced in their entirety with Schedule 1.1(d) and Schedule 1.1(e) attached
hereto.

ARTICLE II

CONDITIONS TO EFFECTIVENESS

     2.1 Closing Conditions. This Amendment shall become effective as of
the day and year set forth above (the “Third Amendment Effective Date”) upon
satisfaction of the following conditions (in form and substance reasonably acceptable
to the Administrative Agent):

     (a) Executed Amendment. The Administrative Agent shall have received a copy of this
Amendment duly executed by each of the Credit Parties and the Administrative Agent, on behalf of
the Required Lenders.

     (b) Executed Consents. The Administrative Agent shall have received executed
consents, in substantially the form of Exhibit A attached hereto, from the Required Lenders
authorizing the Administrative Agent to enter into this Amendment on their behalf. The delivery by
the Administrative Agent of its signature page to this Amendment shall constitute conclusive
evidence that the consents from the Required Lenders have been obtained.

     (c) Payment of Fees. The Administrative Agent shall have received, for itself and the
Lenders, all fees owing pursuant to the engagement letter between the Administrative Agent, the
Arranger and the Borrower dated February 27, 2009.

     (d) Other Fees and Expenses. The Borrower shall have paid in full all reasonable
out-of-pocket fees and expenses of the Administrative Agent in connection with the preparation,
execution and delivery of this Amendment, including without limitation, the reasonable fees and
expenses of Moore & Van Allen PLLC.

     (e) Miscellaneous. All other documents and legal matters in connection with the
transactions contemplated by this Amendment shall be reasonably satisfactory in form and substance
to the Administrative Agent and its counsel.

ARTICLE III

MISCELLANEOUS

     3.1 Amended Terms. On and after the Third Amendment Effective Date, all references to
the Credit Agreement in each of the Credit Documents shall hereafter mean the Credit Agreement as
amended by this Amendment. Except as specifically amended hereby or otherwise agreed, the Credit
Agreement is hereby ratified and confirmed and shall remain in full force and effect according to
its terms.

3

 

     3.2 Representations and Warranties of Credit Parties. Each of the Credit Parties
represents and warrants as follows:

     (a) It has taken all necessary action to authorize the execution, delivery and
performance of this Amendment.

     (b) This Amendment has been duly executed and delivered by such Person and constitutes
such Person’s legal, valid and binding obligations, enforceable in accordance with its
terms, except as such enforceability may be subject to (i) bankruptcy, insolvency,
reorganization, fraudulent conveyance or transfer, moratorium or similar laws affecting
creditors’ rights generally and (ii) general principles of equity (regardless of whether
such enforceability is considered in a proceeding at law or in equity).

     (c) No consent, approval, authorization or order of, or filing, registration or
qualification with, any court or governmental authority or third party is required in
connection with the execution, delivery or performance by such Person of this Amendment.

     (d) After giving effect to this Amendment, the representations and warranties set forth
in Article III of the Credit Agreement are true and correct in all material respects as of
the date hereof (except for those which expressly relate to an earlier date).

     (e) After giving effect to this Amendment, no event has occurred and is continuing
which constitutes a Default or an Event of Default.

     (f) The Security Documents continue to create a valid security interest in, and Lien
upon, the Collateral, in favor of the Administrative Agent, for the benefit of the Lenders,
which security interests and Liens are perfected in accordance with the terms of the
Security Documents and prior to all Liens other than Permitted Liens.

     (g) Except as specifically provided in this Amendment, the Credit Party Obligations are
not reduced or modified by this Amendment and are not subject to any offsets, defenses or
counterclaims.

     3.3 Reaffirmation of Credit Party Obligations. Each Credit Party hereby ratifies the
Credit Agreement and acknowledges and reaffirms (a) that it is bound by all terms of the Credit
Agreement applicable to it and (b) that it is responsible for the observance and full performance
of its respective Credit Party Obligations.

     3.4 Credit Document. This Amendment shall constitute a Credit Document under the
terms of the Credit Agreement.

     3.5 Further Assurances. The Credit Parties agree to promptly take such action, upon
the request of the Administrative Agent, as is necessary to carry out the intent of this Amendment.

4

 

     3.6 Entirety. This Amendment and the other Credit Documents embody the entire
agreement among the parties hereto and supersede all prior agreements and understandings, oral or
written, if any, relating to the subject matter hereof.

     3.7 Counterparts; Telecopy. This Amendment may be executed in any number of
counterparts, each of which when so executed and delivered shall be an original, but all of which
shall constitute one and the same instrument. Delivery of an executed counterpart to this
Amendment by telecopy or other electronic means shall be effective as an original and shall
constitute a representation that an original will be delivered.

     3.8 GOVERNING LAW. THIS AMENDMENT SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND
ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK (INCLUDING SECTIONS 5-1401 AND 5-1402
OF THE NEW YORK GENERAL OBLIGATIONS LAW).

     3.9 Successors and Assigns. This Amendment shall be binding upon and inure to the
benefit of the parties hereto and their respective successors and permitted assigns.

     3.10 Consent to Jurisdiction; Service of Process; Waiver of Jury Trial. The
jurisdiction, services of process and waiver of jury trial provisions set forth in Sections 9.14
and 9.17 of the Credit Agreement are hereby incorporated by reference, mutatis mutandis.

[remainder of page intentionally left blank]

5

 

BELDEN INC.

THIRD AMENDMENT TO CREDIT AGREEMENT

     IN WITNESS WHEREOF the Credit Parties and the Administrative Agent (on behalf of the Required
Lenders) have caused this Amendment to be duly executed on the date first above written.

	 	 	 	 	 	 	 
	BORROWER:	 	BELDEN INC. (formerly known as Belden CDT Inc.),
	 	 	a Delaware corporation
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Stephen H. Johnson	 	 
	 

	 	 	 	 	 	 
	 	 	Name: Stephen H. Johnson
	 	 	Title: Treasurer
	 
	 	 	 	 	 	 
	GUARANTORS:	 	BELDEN WIRE & CABLE COMPANY,
	 	 	a Delaware corporation
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Stephen H. Johnson	 	 
	 

	 	 	 	 	 	 
	 	 	Name: Stephen H. Johnson
	 	 	Title: Treasurer
	 
	 	 	 	 	 	 
	 	 	BELDEN CDT NETWORKING, INC.,
	 	 	a Washington corporation
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Stephen H. Johnson	 	 
	 

	 	 	 	 	 	 
	 	 	Name: Stephen H. Johnson
	 	 	Title: Treasurer
	 
	 	 	 	 	 	 
	 	 	NORDX/CDT CORP.,
	 	 	a Delaware corporation
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Stephen H. Johnson	 	 
	 

	 	 	 	 	 	 
	 	 	Name: Stephen H. Johnson
	 	 	Title: Treasurer
	 
	 	 	 	 	 	 
	 	 	THERMAX/CDT, INC.,
	 	 	a Delaware corporation
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Stephen H. Johnson	 	 
	 

	 	 	 	 	 	 
	 	 	Name: Stephen H. Johnson
	 	 	Title: Treasurer

 

 

	 	 	 	 	 	 	 
	 	 	BELDEN HOLDINGS, INC.,
	 	 	a Delaware corporation
	 
	 

	 	By:
	 	/s/ Stephen H. Johnson
 

	 	 
	 	 	Name: Stephen H. Johnson
	 	 	Title: Treasurer
	 
	 	 	 	 	 	 
	 	 	BELDEN TECHNOLOGIES, INC.,
	 	 	a Delaware corporation
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Stephen H. Johnson
 

	 	 
	 	 	Name: Stephen H. Johnson
	 	 	Title: Treasurer
	 
	 	 	 	 	 	 
	 	 	BELDEN 1993 INC. (formerly known as Belden Inc.),
	 	 	a Delaware corporation
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Stephen H. Johnson
 

	 	 
	 	 	Name: Stephen H. Johnson
	 	 	Title: Treasurer
	 
	 	 	 	 	 	 
	 	 	CDT INTERNATIONAL HOLDINGS INC.,
	 	 	a Delaware corporation
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Stephen H. Johnson
 

	 	 
	 	 	Name: Stephen H. Johnson
	 	 	Title: Treasurer

 

 

BELDEN INC.

THIRD AMENDMENT TO CREDIT AGREEMENT

	 	 	 	 	 	 	 
	ADMINISTRATIVE AGENT:	 	WACHOVIA BANK, NATIONAL ASSOCIATION,
	 	 	as a Lender and as Administrative Agent on behalf of the
	 	 	Required Lenders
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ C. Jeffrey Seaton
 

	 	 
	 	 	Name: C. Jeffrey Seaton
	 	 	Title: Managing Director

 

 

EXHIBIT A

FORM OF

LENDER CONSENT

See Attached.

 

 

LENDER CONSENT

     This Lender Consent is given pursuant to the Credit Agreement, dated as of January 24, 2006
(as previously amended and modified, the “Credit Agreement”; and as further amended by the
Amendment (as hereinafter defined), the “Amended Credit Agreement”), by and among BELDEN
INC. (formerly known as Belden CDT Inc.), a Delaware corporation (the “Borrower”), those
Material Domestic Subsidiaries of the Borrower party thereto (each a “Guarantor” and
collectively, the “Guarantors”), the lenders and other financial institutions from time to
time party thereto (the “Lenders”) and WACHOVIA BANK, NATIONAL ASSOCIATION, as
administrative agent on behalf of the Lenders (in such capacity, the “Administrative
Agent”). Capitalized terms used herein shall have the meanings ascribed thereto in the Credit
Agreement unless otherwise defined herein.

     The undersigned hereby approves the Third Amendment to Credit Agreement (the
“Amendment”), dated as of March ___, 2009, by and among the Borrower, the Guarantors party
thereto and the Administrative Agent and hereby authorizes the Administrative Agent to execute and
deliver the Amendment on its behalf and, by its execution below, the undersigned agrees to be bound
by the terms and conditions of the Amendment and the Amended Credit Agreement.

     Delivery of this Lender Consent by telecopy shall be effective as an original.

     A duly authorized officer of the undersigned has executed this Lender Consent as of
[___], 2009.

	 	 	 	 	 	 	 
	 
	 	 	 	, 	 
	 	 	as a Lender	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	Name:
	 	 

	 	 
	 

	 	 	 	 	 	 
	 

	 	Title:	 	 	 	 
	 

	 	 	 	 

	 	 

 

 

SCHEDULE 1.1(D)

Belden Inc.

Third Amendment

Schedule 1.1(d)

in thousands US dollars

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	2008 1st	 	 	2008 2nd	 	 	2008 3rd	 	 	2008 4th	 	 	 	 
	Restructuring Charges (Cash)	 	Quarter	 	 	Quarter	 	 	Quarter	 	 	Quarter	 	 	Total	 
	EMEA Restructuring
	 	 	4,826	 	 	 	160	 	 	 	—	 	 	 	—	 	 	 	4,986	 
	Reduction in Force
	 	 	612	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	612	 
	Voluntary Separation Program
	 	 	6,479	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	6,479	 
	Global Restructuring
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	26,290	 	 	 	26,290	 
	 	 	 
	 
	 	 	11,917	 	 	 	160	 	 	 	—	 	 	 	26,290	 	 	 	38,367	 

 

 

SCHEDULE 1.1(E)

Belden Inc.

Third Amendment

Schedule 1.1(e)

in thousands US dollars

	 	 	 	 	 
	Restructuring Charges (Cash)	 	 	 	 
	Global Restructuring
	 	 	20,000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}]]